摘要
目的研究罗沙司他联合左卡尼汀对肾性贫血患者红细胞(red blood cell,RBC)、转铁蛋白饱和度(transferrin saturation,TSAT)、转铁蛋白(transferrin,TRF)水平的影响。方法选取2020年2月至2021年4月于台州市中心医院就诊的158例肾性贫血患者为研究对象,根据随机数字表法将其分为对照组和研究组,每组各79例。对照组患者给予左卡尼汀治疗,研究组患者给予左卡尼汀联合罗沙司他治疗。比较两组患者治疗前后的肿瘤坏死因子(tumor necrosis factor,TNF)、C反应蛋白(C-reactive protein,CRP)、白细胞介素-6(interleukin-6,IL-6)、TRF、血红蛋白(hemoglobin,Hb)、血清铁蛋白(serum ferritin,SF)、TSAT、RBC水平,统计患者的临床疗效及不良反应。结果治疗后,两组患者的TNF、CRP、IL-6水平显著低于本组治疗前,TRF、TSAT、RBC、Hb、SF水平均显著高于本组治疗前(P<0.05),且研究组患者的TNF、CRP、IL-6水平显著低于对照组,TRF、TSAT、RBC、Hb、SF水平均显著高于对照组(P<0.05)。研究组患者的治疗总有效率显著高于对照组(P<0.05)。研究组患者的总不良反应略多于对照组,但两组比较差异无统计学意义(P>0.05)。结论罗沙司他联合左卡尼汀可显著改善肾性贫血患者的RBC、TSAT、TRF水平及临床症状,促进患者身体恢复,效果较为理想。
Objective To investigate the effects of roxadustat combined with levocarnitine on red blood cell(RBC),transferrin saturation(TSAT)and transferrin(TRF)levels in patients with renal anemia.Methods A total of 158 renal anemia patients treated in Taizhou Central Hospital from February 2020 to April 2021 were selected as the study subjects and divided into control group and study group according to the random number table method,with 79 patients in each group.The patients in control group were treated with levocarnitine,and the patients in study group were treated with levocarnitine combined with roxadustat.The levels of tumor necrosis factor(TNF),C-reactive protein(CRP),interleukin-6(IL-6),TRF,hemoglobin(Hb),serum ferritin(SF),TSAT and RBC were compared between the two groups before and after treatment,and the clinical efficacy and adverse reactions were counted.Results After treatment,the levels of TNF,CRP and IL-6 in the two groups were significantly lower than those before treatment,the levels of TRF,TSAT,RBC,Hb and SF were significantly higher than those before treatment(P<0.05).The levels of TNF,CRP and IL-6 in study group were significantly lower than those in control group,and the levels of TRF,TSAT,RBC,Hb and SF in study group were significantly higher than those in control group(P<0.05).The total effective rate of study group was significantly higher than that of control group(P<0.05).The total adverse reactions in study group were slightly higher than those in control group,but there was no significant difference between the two groups(P>0.05).Conclusion Roxadustat combined with levocarnitine can significantly improve RBC,TSAT,TRF levels and clinical symptoms in patients with renal anemia,and promote the physical recovery of patients,and the effect is ideal.
作者
孙霄童
姚虹
余海峰
SUN Xiaotong;YAO Hong;YU Haifeng(Department of Nephrology,Taizhou Central Hospital(Taizhou University Hospital),Zhejiang,Taizhou 318000,China;Department of Rehabilitation,Taizhou Hospital of Zhejiang Province,Zhejiang,Taizhou 317000,China)
出处
《中国现代医生》
2022年第31期91-94,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2020KY1042)。
